Altered gene expression in spontaneous hepatocellular carcinomas from male B6C3F1 mice

Molecular Carcinogenesis

Volumn 19, Issue 1, 1997, Pages 31-38

  Romach, Elizabeth H ^a   Goldsworthy, Thomas L ^a   Maronpot, Robert R ^b   Fox, Tony R ^a,c  

^a CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

cyclin D1; Insulin like growth factor II; Liver cancer; Oncogenes

Indexed keywords

CYCLIN D1; SOMATOMEDIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL;

ANIMALS; CYCLIN D1; CYCLINS; GENE EXPRESSION; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED STRAINS; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 0030955835     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199705)19:1<31::AID-MC5>3.0.CO;2-Q     Document Type: Article

References (38)

1. Chen C. NTP Technical Report on the Toxicology and Characterization Studies of Dimethylmorphoeno-phosphoramidate in F344/n Rats and B6C3F1 Mice. CAS No. 597-25-1. Greene Publishing Associates and Wiley-Interscience, John Wiley and Sons, New York, 1989.
2. Grasso P, Hardy J. Strain differences in natural incidences and response to carcinogenesis. In: Butler WH, Newberne PM (eds), Mouse Hepatic Neoplasia. Elsevier, New York, 1975, pp 111.
3. Maronpot RR, Fox T, Malarkey DE, Goldsworthy TL. Mutations in the ras proto-oncogene: Clues to etiology and molecular pathoqenesis of mouse liver tumors. Toxicology 101:125-156, 1995.
4. Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4:715-724, 1989.
5. Pasquinelli C, Bhavani K, Chisari FV. Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice. Cancer Res 52:2823-2829, 1992.
6. Lee GH, Merlino G, Fausto N. Development of liver tumors in transforming growth factor alpha transgenic mice. Cancer Res 52:5162-5170, 1992.
7. Takagi H, Sharp R, Hammermeister C, et al. Molecular and genetic analysis of liver oncogenesis in transforming growth factor α transgenic mice. Cancer Res 52:5171-5177, 1992.
8. Nishida N, Fukuda Y, Komeda T, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 54:3107-3110, 1994.
9. Maronpot RR, Hasemann JJ, Boorman GA, Eustus SE Rao GN, Huff JR. Liver lesions in B6C3F1 mice: The National Toxicology Program experience and position. Arch Toxicol 10:10-26, 1987.
10. Motokura T, Bloom T, Kim KG, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350:512-515, 1991.
11. Frye RA, Benz CC, Liu E. Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 4:1153-1157, 1989.
12. Garte SJ. The c-myc oncogene in tumor progression. Crit Rev Oncog 4:435-449, 1993.
13. Cohick WS, Clemmons DR. The insulin-like growth factors. Annu Rev Physiol 55:131-153, 1993.
14. Gluckman PD, Ambler GR. What is the function of circulating insulin-like growth factor-2 in postnatal life? Mol Cell Endocrinol 92:C1-C3, 1993.
15. Blatt J, White C, Dienes S, Friedman H, Foley TP. Production of an insulin-like growth factor by osteosarcoma. Biochem Biophys Res Commun 123:373-376, 1984.
16. Fu XX, Su CY, Lee Y, et al. Insulin-like growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers. J Virol 62:3422-3430, 1988.
17. Yang DY, Rogler CE. Analysis of insulin-like growth factor II (IGI-II) expression in neoplastic nodules and hepatocellular carcinomas of woodchucks utilizing in situ hybridization and immunocytochemistry. Carcinogenesis 12:1893-1901, 1991.
18. Cariani E, Lasserre C, Seurin D, et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 48:6844-6849, 1988.
19. Rogler CE. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 169:13779-13784, 1994.
20. Drummold IA, Madden SL, Rohvernutter P, Bell GI, Sukhatve VP, Rauscher FJ. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 257:674-678, 1992.
21. Thompson NL, Mead JE, Braun E, Goyette M, Sand PR, Fausto N. Sequential proto-oncogene expression during rat liver regeneration. Cancer Res 46:3111-3117, 1986.
22. Zhang X-K, Wang Z, Lee A, Huang D-P, Chiu J-F. Differential expression of cellular oncogenes during rat liver development. Cancer Lett 41:147-155, 1988.
23. Zimmerman K, Alt WE. Expression and function of myc family genes. Crit Rev Oncog 2:75-95, 1990.
24. Campisi J, Gray HE, Pardee AB, Dean M, Sonenshein GE. Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation. Cell 36:241-247, 1984.
25. Lammie GA, Fantl V, Smith R, et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6:439-444, 1991.
26. Zhang YJ, Jiang W, Chen CJ, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 196:1010-1016, 1993.
27. Bianchi AB, Fischer SM, Robles AI, Rinchik EM, Conti CJ. Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene 8:1127-1133, 1993.
28. Robles A, Conti CJ. Early expression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis 16:781-786, 1995.
29. Jiang W, Kahn SM, Zhou P, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression, and gene expression. Oncogene 8:3447-3457, 1993.
30. Mead JE, Fausto N. Transforming growth factor alpha may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci USA 86:1558-1562, 1989.
31. Yeh Y, Tsai J, Chuang L, et al. Elevation of TGFα and alpha feto-protein levels in patients with hepatocellular carcinoma. Cancer Res 47:896-901, 1987.
32. Liu C, Tsao MS, Grisham JW. Transforming growth factors produced by normal and neoplastically transformed rat liver epithelial cells in culture. Cancer Res 48:850-855, 1988.
33. Dragan Y, Teeguarden J, Cambell H, Hsia S, Pitot H. The quantitation of altered hepatic foci during multistage hepatocarcinogenesis in the rat: Transforming growth factor alpha expression as a marker for the stage of progression. Cancer Lett 93:73-83, 1995.
34. Earp HS, O'Keef EJ. Epidermal growth factor receptor number decreases during rat liver regeneration. J Clin Invest 67:1580-1583, 1981.
35. Eckl PM, Meyer SA, Rive'Whitcombe W, Jirtle RL. Phenobarbital reduces EGF receptors and the ability of physiological concentrations of calcium to suppress hepatocyte proliferation. Carcinogenesis 9:479-483, 1988.
36. Hwang DL, Roitman A, Lev-Ran A, Carr BI. Chronic treatment wrth phenobarbital decreases the expression of rat liver EGF and insulin receptors. Biochem Biophys Res Commun 135:501-506, 1986.
37. Orton TC, Doughty SE, Kalinowski AE, Lord PG, Wadsworth PF. Expression of growth factors and growth factor receptors in the liver of C57BL/10J mice following administration of phenobarbitone. Carcinogenesis 17:973-981, 1996.
38. Hsieh LL, Hsiao W-L, Peraino C, Maronpot RR, Weinstein IB. Expression of retroviral sequences and oncogenes in rat liver tumors induced by diethylnitrosamine. Cancer Res 47:3421-3424, 1987.